Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Eterna Therapeutics Inc. (ERNA:NASDAQ), powered by AI.
Eterna Therapeutics Inc. is currently trading at $0.15. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Eterna Therapeutics Inc. on Alpha Lenz.
Eterna Therapeutics Inc.'s P/E ratio is -0.0.
“Eterna Therapeutics Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -2264.3%.”
Ask for details →Eterna Therapeutics Inc. is a biopharmaceutical company dedicated to revolutionizing cell and gene therapies through innovative biotechnology solutions. The company's primary function is to develop groundbreaking treatments targeting rare and complex diseases by utilizing advanced genomic editing and delivery systems. Eterna Therapeutics focuses on leveraging its proprietary technology across various fields, including oncology, regenerative medicine, and genetic disorders. With a mission to address significant unmet medical needs, the company is at the forefront of creating therapies that are designed to be safer and more effective. Eterna Therapeutics' ongoing research and development activities position it as a pivotal player in the rapidly evolving biopharmaceutical landscape. Through strategic partnerships and a commitment to scientific excellence, the company aims to transform how the medical community approaches the treatment of challenging health conditions, providing new pathways to health and wellness for patients worldwide.
“Eterna Therapeutics Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -2264.3%.”
Ask for details →Eterna Therapeutics Inc. (ticker: ERNA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 6 employees. Market cap is $134,286.
The current price is $0.148 with a P/E ratio of -0x and P/B of 0.08x.
ROE is -2264.31% and operating margin is -2963.92%. Annual revenue is $582,000.